Table 1 Patients’ characteristics by the two waves of the COVID-19 pandemic.
From: Second versus first wave of COVID-19 in patients with MPN
First wave | Second wave | p value | |
|---|---|---|---|
N = 175 | N = 304 | ||
MPN diagnosis | |||
ET | 51 (29.1%) | 110 (36.2%) | 0.12 |
PV | 46 (26.3%) | 89 (29.3%) | 0.48 |
MF | 60 (34.3%) | 74 (24.3%) | 0.020 |
pre-PMF | 18 (10.3%) | 31 (10.2%) | 0.98 |
Treatments at last MPN f-up before Covid-19 | |||
Cytoreduction | 141 (80.6%) | 233 (77.2%) | 0.38 |
Hydroxyurea | 79 (56.0%) | 161 (68.8%) | 0.092 |
Anagrelide | 8 (5.7%) | 10 (4.3%) | 0.48 |
Interferon | 4 (2.8%) | 7 (3.0%) | 0.99 |
Ruxolitinib | 45 (31.9%) | 44 (18.8%) | 0.002 |
Other | 5 (3.5%) | 12 (5.1%) | 0.53 |
ASA | 104 (59.4%) | 180 (59.4%) | 1.00 |
At Covid-19 diagnosis | |||
Sex | 0.037 | ||
Female | 73 (41.7%) | 158 (52.0%) | |
Male | 102 (58.3%) | 146 (48.0%) | |
Age | 71.0 (60.0–79.9) | 63.3 (54.5–73.8) | <0.001 |
<60 yrs | 42 (24.1%) | 117 (38.5%) | |
60–70 yrs | 37 (21.3%) | 83 (27.3%) | |
>70 yrs | 95 (54.6%) | 104 (34.2%) | |
Patient disposition | <0.001 | ||
Home | 40 (22.9%) | 208 (68.4%) | |
Regular ward | 116 (66.3%) | 88 (28.9%) | |
ICU | 19 (10.9%) | 8 (2.6%) | |
Respiratory supplement need | 103 (59.2%) | 83 (27.6%) | <0.001 |
Not invasive | 99 (96.1%) | 79 (95.2%) | 0.75 |
Invasive | 20 (19.4%) | 7 (8.5%) | 0.037 |
O2 saturation % | 93.0 (88.0–96.0) | 96.0 (90.0–98.0) | <0.001 |
Symptoms | |||
Fever | 141 (80.6%) | 192 (63.2%) | <0.001 |
Cough | 96 (54.9%) | 132 (43.4%) | 0.016 |
Dispnea | 98 (56.0%) | 88 (28.9%) | <0.001 |
Systemic | 36 (20.6%) | 30 (9.9%) | 0.001 |
Gastrointestinal | 22 (12.6%) | 26 (8.6%) | 0.16 |
Comorbidities | 130 (74.3%) | 192 (63.2%) | 0.012 |
Asthma | 3 (1.7%) | 8 (2.6%) | 0.53 |
Cerebrovascular | 23 (13.2%) | 28 (9.2%) | 0.18 |
Kidney impairment | 19 (10.9%) | 5 (1.7%) | <0.001 |
Heart disease | 25 (14.5%) | 25 (8.3%) | 0.035 |
COPD | 25 (14.4%) | 19 (6.3%) | 0.003 |
Smoke | 35 (23.0%) | 47 (16.2%) | 0.077 |
Hyperlipidemia | 47 (28.0%) | 56 (18.5%) | 0.018 |
Obesity | 21 (13.1%) | 25 (8.3%) | 0.098 |
Reumatic disease | 11 (6.4%) | 13 (4.3%) | 0.32 |
Hypertension | 104 (60.8%) | 128 (42.5%) | <0.001 |
Diabetes | 23 (13.4%) | 27 (8.9%) | 0.13 |
Chemistry | |||
Hemoglobin g/dL | 12.4 (10.0–13.6) | 12.9 (11.1–13.9) | 0.019 |
Hematocrit % | 38.4 (32.0–42.4) | 39.0 (34.9–43.9) | 0.069 |
WBC x 109/L | 6.5 (4.6–10.1) | 6.8 (5.1–9.8) | 0.52 |
Neutrophils % | 75.9 (66.0–83.0) | 71.0 (62.5–80.0) | 0.053 |
Lymphocytes % | 14.0 (9.0–20.0) | 17.6 (10.2–25.0) | 0.022 |
N/L ratio | 5.4 (3.4–8.9) | 4.1 (2.6–8.4) | 0.038 |
Platelets x 109/L | 252.0 (152.0–394.0) | 350.0 (224.0–456.0) | <0.001 |
LDH U/L | 426.0 (264.5–641.5) | 356.0 (229.0–622.0) | 0.15 |
CRP mg/L | 74.0 (26.0–156.8) | 51.5 (10.3–100.0) | 0.008 |
D-dimer ng/ml | 801.0 (398.0–1655.0) | 924.5 (480.0–2340.0) | 0.20 |
Covid-directed treatments | |||
Steroids | 45 (27.8%) | 121 (40.3%) | 0.007 |
Antibiotics | 114 (70.4%) | 123 (41.0%) | <0.001 |
Hydroxychloroquine | 100 (60.2%) | 9 (3.0%) | <0.001 |
Antivirals | 57 (34.3%) | 19 (6.4%) | <0.001 |
Experimentals | 19 (11.2%) | 12 (4.0%) | 0.002 |
Antithrombotics | 93 (56.0%) | 114 (38.4%) | <0.001 |
MPN-directed treatment change | |||
Hydroxyurea discontinuation | 9 (11.3%) | 11 (6.6%) | 0.21 |
Anagrelide discontinuation | 1 (12.5%) | 2 (20.0%) | 0.67 |
Interferon discontinuation | 1 (25.0%) | 1 (14.3%) | 0.66 |
Ruxolitinib discontinuation | 11 (23.9%) | 4 (8.7%) | 0.048 |
Outcomes of the acute phase | |||
Death | 50 (28.6%) | 26 (8.6%) | <0.001 |
Time to death (days) | 9.5 (4–16) | 11.0 (6–20) | 0.673 |
Thrombosis | 14 (8.0%) | 5 (1.6%) | 0.001 |
Time to thrombosis (days) | 11.5 (4.0–25.0) | 1.0 (1.0–6.0) | 0.52 |
Arterial | 3 (1.7%) | 1 (0.3%) | 0.141 |
Venous | 12 (6.9%) | 4 (1.3%) | 0.002 |
